

Curriculum Vitae

Personal information **Annemieke Boot**

Work experience

2007-present Paediatric endocrinologist in University Medical Center Groningen - Beatrix Children's Hospital, Groningen, the Netherlands

2005-2006 Paediatrician in Medical Center Rijnmond Zuid, Rotterdam, 0.75 fte.

2004-2006 Paediatric endocrinologist, Erasmus MC- Sophia Children's Hospital, Rotterdam, 2005 - 2006 0.2 fte

2002-2004 Fellow paediatric endocrinology in Sophia's Children's Hospital Rotterdam.

1997-2002 Specialist training in paediatrics in Sophia Children's Hospital, Rotterdam.

1992-1997 PhD study in bone mineral density, bone metabolism and body composition in children, Sophia Children's Hospital, Rotterdam.

1990-1992 Medical Doctor and District Health Officer in Mangochi District Hospital, Mangochi, Malawi, Africa.

1989-1990 Medical Doctor working in surgery, gynaecology-obstetrics, internal medicine and paediatrics in Queen Elizabeth Central Hospital, Blantyre, Malawi, Africa

1988-1989 General physician at a Casualty "Kruispost" in Amsterdam

1984 Internship in different hospitals in Kenya (Kenyatta National Hospital, Nairobi and Mission Hospital Mumias) and Uganda (Masaka), Sept. - Dec.

Education and training

1997-2002 Specialist training in paediatrics in Sophia Children's Hospital, Rotterdam.

1992-1997 PhD study in bone mineral density, bone metabolism and body composition in children, Sophia Children's Hospital, Rotterdam.

1980-1988 Medical school, University of Utrecht

Courses:

2015, 2019, 2023 update of certificate Good Clinical Practice (BROK)

2013 March 15 Metabolic Bone Diseases, VUMC Amsterdam

2011 Good Clinical Practice (BROK) certificate

2006-2007 Master class programme paediatric endocrinology, the Netherlands

2003 Oct 30-31 Workshop Molecular Biology, European School for Science Education

2003 Aug 25-29 Genetic Epidemiology of Complex Diseases, Erasmus Summer Programme

2001 and 2006 Advanced Paediatric Life Support

2001 Summer school of the European Society of Paediatric Endocrinology Montreal, Canada.

1994 Cambridge Certificate Proficiency in English

1993 Biostatistics course, Erasmus University, Rotterdam

1988 Diploma in Tropical Medicine and Hygiene, Tropical Institute, Amsterdam

1984 Leprosy course, Alupe Hospital, Kenya

Additional information

Publications

- 1) Boot AM, Nauta J, Hokken-Koelega ACS, Pols HAP, de Ridder MAJ, de Muinck Keizer-Schrama SMPF. Renal transplantation and osteoporosis. Arch Dis Child 1995; 72: 502-6.
- 2) Boot AM, de Ridder MAJ, Pols HAP, Krenning EP, de Muinck Keizer-Schrama SMPF. Bone mineral density of children and adolescents; relation to puberty, calcium intake and physical activity. J Clin Endocrinol Metab 1997; 82:57-62.
- 3) Boot AM, Bouquet J, de Ridder MAJ, Krenning EP, de Muinck Keizer-Schrama SMPF. Determinants of body composition, measured by dual-energy x-ray absorptiometry, in Dutch children and adolescents. Am J Clin Nutr 1997; 66: 232-8.
- 4) Boot AM, de Jongste JC, Verberne AAPH, Pols HAP, de Muinck Keizer-Schrama SMPF. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Ped Pulmonology 1997; 24: 379-84.
- 5) Boot AM, Engels MAMJ, Boerma GJM, Krenning EP, de Muinck Keizer-Schrama SMPF. Changes in bone mineral density, body composition and lipid metabolism during growth hormone-treatment in children with growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 2423-8.
- 6) Boot AM. Bone mineral density and body composition of children and adolescents in health and disease. Thesis. 1997.
- 7) Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SMPF. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998; 42:188-94.
- 8) Boot AM, de Muinck Keizer-Schrama SMPF, Pols HAP, Krenning EP, Drop SLS. Bone mineral density and

- body composition before and during treatment with gonadotrophin releasing hormone agonist in children with central precocious and early puberty. *J Clin Endocrinol Metab* 1998; 83: 370-3.
- 9) Boot AM, Nauta J, de Jong MCJW, Groothoff JW, Lilien M, van Wijk JAE, Kist-van Holthe JE, Hokken-Koelega ACS, Pols HAP, de Muinck Keizer-Schrama SMPF. Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment. *Clin Endocrinol* 1998; 49:665-72.
- 10) Boot AM, van den Heuvel-Eibrink MM, Hahlen K, Krenning EP, de Muinck Keizer-Schrama SMPF. Bone mineral density in children with acute lymphoblastic leukemia. *Eur J Cancer* 1999;35:1693-7.
- 11) Boot AM. Botdichtheid bij kinderen. *Tijdschrift voor Huisartsgeneeskunde* 1999; 7/8:366-71.
- 12) Boot AM. Determinanten van botdichtheid op de kinderleeftijd. *Nederlands Tijdschrift voor Osteoporose*. 1999; 4: 86-9.
- 13) van der Sluis IM, Boot AM, Nauta J, Hop WCJ, Jong MCJW de, Uien MR, Groothoff JW, Wijk AE van, Pols HAP, Hokken-Koelega ACS, Muinck Keizer-Schrama SMPF de. Bone density and body composition in chronic renal failure: effects of growth hormone treatment. *Ped Nephrol* 2000; 15: 221-8.
- 14) van der Sluis IM, Boot AM, Krenning EP, Drop SLS, de Muinck Keizer-Schrama SMPF. Long-term followup of bone density and body composition of children with precocious and early puberty before, during and after cessation of gonadotrophin-releasing hormone agonist therapy. *J Clin Endocrinol Metab* 2002; 87: 506-12.
- 15) van der Sluis IM, Boot AM, Hop WC, de Rijke YB, Krenning EP, de Muinck Keizer-Schrama SMPF. Longterm effects of growth hormone therapy on bone mineral density, body composition and serum lipid levels in growth hormone deficient children: 6 years follow-up. *Horm Res* 2002; 58: 207-14.
- 16) van der Sluis IM, de Ridder MAJ, Boot AM, Krenning EP, de Muinck Keizer-Schrama SMPF. Reference data for bone density and body composition measured with dual energy X-ray absorptiometry in Caucasian children and young adults. *Arch Dis Childh* 2002; 87:341-7.
- 17) Groeneweg M, Tan S, Boot AM, de Jongste JC, Bouquet J, Sinaasappel M. Assessment of nutritional status in children with cystic fibrosis: conventional anthropometry and bioelectrical impedance analysis. A cross-sectional study in Dutch patients. *J Cyst Fibrosis* 2002; 1: 276-80.
- 18) Boot AM. Editorial: Body composition and bone mineral density in adolescents with partial growth hormone deficiency. *J Clin Endocrinol Metab* 2003; 88:5099-5100.
- 19) Van Rijn RR, Grootfaam DS, Lequin MH, Boot AM, Van Beek RD, Hop WC, Van Kuijk C. Digital Radiogrammetry of the Hand in a pediatric and Adolescent Dutch Caucasian Population: Normative Data and Measurements in Children with Inflammatory Bowel Disease and Juvenile Chronic Arthritis. *Calcif Tissue Int*. 2004; 74:342-350.
- 20) Boot AM, van der Sluis IM, de Muinck Keizer-Schrama, van Meurs JBJ, Krenning EP, Pols HAP, Uitterlinden AG. Estrogen receptor a gene polymorphism and bone mineral density in healthy children and young adults. *Calcif Tiss Int* 2004; 74:495-500.
- 21) Dijkstra SH, Arpaci G, Huijsman WA, Boot AM, van den Akker ELT. Convulsies bij allochtone pasgeborenen door hypovitaminose D bij de moeder. *N Tijdschr Geneesk* 2005; 5: 257-60.
- 22) De la Marche W, Prinsen K, Boot AM, Ferdinand RF. No aggression in a 4-year-old boy with an androgenproducingtumour: Case Report. *Ann Gen Psychiatry*. 2005 Oct 3;4:17.
- 23) van Rijn RR, Boot AM, Wittenberg R, van der Sluis IM, van den Heuvel-Eibrink MM, Lequin MH, de MuinckKeizer- Schrama SMPF, Van Kuijk C. Direct X-ray Radiogrammetry versus Dual-energy X-ray Absorptiometry; assessment of bone density in children treated for Acute LymphoblasticLeukemia and Growth Hormone Deficiency. *Ped Radiology* 2006; Jan 24:1-6.
- 24) Boot AM. Body composition in paediatric growth hormone deficiency. Proceedings of growth hormone and growth factors in endocrinology and metabolism. 4-5 March 2005. Athens, Greece.
- 25) Boot AM, de Coe IFM, Pais G, de Muinck Keizer-Schrama SPMF. Muscle weakness as presenting symptom of osteogenesis imperfecta. *Eur J Ped* 2006; 165: 392-394.
- 26) van der Sluis IM, Boot AM, Vernooij M, Meradji M, Kroon AA. Idiopathic infantile arterial calcification: clinical presentation, therapy and long-term follow-up.. *Eur J Ped* 2006;165:590-3.
- 27) Walenkamp MJE, de Muinck Keizer SMPF, de Mos M, Kalf ME, Duyvenvoorde HA, Boot AM, Kant SG, White SJ, Losekoot M, Dunnen JT, Karperien M, Wit JM. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the IGF-1 receptor due to terminal 15q26.2>qter deletion. *J Clin Endocrinol Metab* 2008;93:2421-5.
- 28) Leunissen RWJ, Stijnen T, Boot AM, Hokken-Koelega ACS. Influence of Birth Size and Body Composition 3 on Bone Mineral Density in Early Adulthood. The PROGRAM-study. *Clin Endocrinol* 2008;69:386-92.
- 29) Boot AM, van der Sluis IM, Krenning EP, de Muinck Keizer-Schrama SMPF. Bone mineral density and body composition in adolescents with childhood onset growth hormone deficiency. . *Horm Res* 2009;71:364-371.
- 30) van Silfhout A, Boot AM, Dijkhuizen T, Hoek A, Nijman R, Sikkema-Raddatz B, Conny Ravenswaaij-Arts MA.A unique 970 kb microdeletion in 9q33.3, including the NR5A1 gene in a 46,XY female. *Eur J of Med Genetics* 2009;52:157-60.
- 31) Roke Y, van Harten PN, Boot AM, Buitelaar JK. Antipsychotic medication in children and adolescents: effects on prolactin level and associated side effects. A descriptive review. *J Child Adolesc Psychopharmacol* 2009; 19:403-14.
- 32) Mergler S, Evenhuis HM, Boot AM, De Man SA, Bindels-De Heus KG, Huijbers WA, Penning C. Epidemiology of low bone mineral density and fractures in children with severe cerebral palsy: a systematic review. *Dev Med Child Neurol* 2009;51:773-8.
- 33) Boot AM, de Ridder MA, van der Sluis IM, van Slobbe I, Krenning EP, de Muinck Keizer-Schrama SM. Peak bone mineral density, lean body mass and fractures. *Bone* 2010; 46:336-41.
- 34) Tamminga N, Boot AM. Pijn, spierzwakte en vermoeidheid als presenterende symptomen van vitamine D deficiëntie, *Tijdschrift voor Kindergeneeskunde* 2010
- 35) Hendriks AE, Boellaard WP, van Gasteren NJ, Romijn JC, de Jong FH, Boot AM, Drop SL. Fatherhood in Tall Men Treated with High-Dose Sex Steroids during Adolescence. *J Clin Endocrinol Metab*. 2010;95:5233-40.
- 36) Hendriks AE, Laven JS, Valkenburg O, Fong SL, Fauser BC, de Ridder MA, de Jong FH, Visser JA, van Ginneken AM, Boot AM, Drop SL. Fertility and Ovarian Function in High-Dose Estrogen-Treated Tall Women. *J Clin Endocrinol Metab*. 2011; 96:1098-1105.
- 37) Boot AM, Krenning EP, de Muinck Keizer-Schrama SMPF. The relation between 25-hydroxyvitamin D with peak bone mineral density and body composition in healthy young adults. *J Ped Endocrinol Metab* 2011; 24(5-6):355-60
- 38) Boot AM, Lumbroso S, Verhoef-Post M, Richter-Unruh A, Looijenga LHJ, Funaro A, Beishuizen A, van Marle A, Drop SLS, Themmen APN. Mutation analysis of the LH receptor gene in Leydig cell adenoma and hyperplasia and functional and biochemical studies of activating mutations of the LH receptor gene. *J Clin Endocrinol Metab*. 2011; 96(7):E1197-205
- 39) Hendriks AE, Brown MR, Boot AM, Oostra BA, Drop SL, Parks JS...Genetic variation in candidate genes like the HMG2A gene in the extremely tall. *Horm Res in Paediatr*. 2011;76(5):307-13.
- 40) Hendriks AE, Brown MR, Boot AM, Oostra BA, de Jong FH, Drop SL, Parks JS. Common Polymorphisms in the GH/IGF-1 Axis Contribute to Growth in Extremely Tall Subjects. *Growth Hormone & IGF Research* 2011 ;21(6):318-24.
- 41) van Egmond ME, Dikkers FG, Boot AM, van Lierop AHJM, Papapoulos SE, van Wattum M, Brouwer OF. A rare cause of facial nerve palsy in children: hyperostosis frontalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review. *Europ J Paediatr Neurol* 2012; 16(6):740-3.
- 42) Hendriks AE, Drop SL, Laven JS, Boot AM. Fertility of tall girls treated with high-dose estrogen, a doseresponse

- relationship. *J Clin Endocrinol Metab* 2012;97(9):3107-14.
- 43) Roke Y, van Harten PN, Buitelaar JK, Tenback DE, de Rijke YB, Boot AM. Antipsychotic-induced hyperprolactinemia and testosterone levels in boys. *Horm Res in Paediatr* 2012; 77(4):235-40.
- 44) Hendriks AEJ, Laven JSE, , Boellaard WPA, de Jong FH, Boot AM, Drop SLS. Vruchtbaarheid na behandeling met hoge dosis geslachtshormonen ter groeiremming. *Ned Tijdschr Geneesk*. 2012;156(14):A3982
- 45) Blijdorp K, van den Heuvel-Eibrink M, Pieters R, Boot A, Sluimer J, van der Lelij AJ, Neggers S. The limited screening value of insulin-like growth factor-I as a marker for alterations in body composition in very long-term adult survivors of childhood cancer. *Pediatr Blood Cancer*. 2012;59(4):711-6.
- 46) Blijdorp K, van den Heuvel-Eibrink MM, Pieters R, Boot AM, Delhanty PJ, van der Lelij AJ, Neggers SJ. Obesity is underestimated using body mass index and waist-hip ratio in long-term adult survivors of childhood cancer. *PLoS One*. 2012;7(8):e43269
- 47) Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN. Risk of hyperprolactinemia and sexual side effects in males 10-20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. *J Child Adolesc Psychopharmacol*. 2012;22(6):432-9.
- 48) Roke Y, van Harten PN, Buitelaar JK, Tenback DE, Quekel LG, de Rijke YB, Boot AM. Bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment. *Eur J Endocrinol*. 2012;167(6):855-63.
- 49) Petkovic V, Miletta MC, Boot AM, Monique Losekoot, Flück CE, Pandey AV, Eblé A, Wit JM, Mullis PE. Short stature in two siblings heterozygous for a novel bioinactive GH mutant (GH-P59S) suggesting that the mutant also affects secretion of the wild-type GH. *Eur J Endocrinol* 2013; 15;168(3):K35-43.
- 50) Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK. The effect of the TaqIA variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. *Pharmacogenet Genomics*. 2013 ;23(9):487-93.
- 51) Liu F, Hendriks AE, Ralf A, Boot AM, Benyi E, Savendahl L, Oostra BA, van Duijn C, Hofman A, Rivadeneira F, Uitterlinden AG, Drop SL, Kayser M. Common DNA variants predict tall stature in Europeans. *Hum Genet*. 2014 133(5):587-97.
- 52) van der Eerden BC, van der Heyden JC, van Hamburg JP, Schreuders-Koedam M, Asmawidjaja PS, de Muinck Keizer-Schrama SM, Boot AM, Lubberts E, Drop SL, van Leeuwen JP. A human vitamin D receptor mutation causes rickets and impaired Th1/Th17 responses. *Bone* 2014 6;69C:6-11.
- 53) Brinksma A, Roodbol PF, Suikers E, Kamps WA, de Bont ES, Boot AM, Burgerhot JG, Tamminga RY, Tissing WJ. Changes in nutritional status in childhood cancer patients: A prospective cohort study. *Clin Nutr* 2015 ;34(1):66-73.
- 54) den Hoed MA, Klap BC, Te Winkel ML, Pieters R, van Waas M, Neggers SJ, Boot AM, Blijdorp K, van Dorp W, Pluijm SM, van den Heuvel-Eibrink MM. Bone mineral density after childhood cancer in 346 longterm adult survivors of childhood cancer. *Osteoporos Int*. 2015;26(2):521-9.
- 55) Saggese G, Vierucci F, Boot AM, Czech-Kowalska J, Weber G, Camargo CA Jr, Mallet E, Fanos M, Shaw NJ, Hollek MF. Vitamin D in childhood and adolescence: an expert position statement. *Eur J Pediatr*. 2015;174(5):565-76.
- 56) Rijks EB, Bongers BC, Vlemmix MJ, Boot AM, van Dijk AT, Sakkers RJ, van Brussel M. Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review. *Horm Res Paediatr*. 2015;84(1):26-42.
- 57) Mergler S, de Man SA, Boot AM, Heus KG, Huijbers WA, van Rijn RR, Penning C, Evenhuis HM. Automated radiogrammetry is a feasible method for measuring bone quality and bone maturation in severely disabled children. *Pediatr Radiol*. 2016; 46(7):1017-22.
- 58) Clement SC, Schouten-van Meeteren AY, Boot AM, Claahsen-van der Grinten HL, Granzen B, Sen Han K, Janssens GO, Michiels EM, van Trotsenburg AS, Vandertop WP, van Vuurden DG, Kremer LC, Caron HN, van Santen HM. Prevalence and Risk Factors of Early Endocrine Disorders in Childhood Brain Tumor Survivors: A Nationwide, Multicenter Study. *J Clin Oncol*. 2016;34(36):4362-4370.
- 59) Goedegebuure WJ, Jonkers F, Boot AM, Bakker-van Waarde W.M., Van Tellingeng V, Heeg M, Odink RJ, Van der Steen MC. Long-term follow-up after bilateral percutaneous epiphysodesis around the knee to reduce excessive predicted final height. *Arch Dis Childh* 2018;103(3):219-223.
- 60) van der Steen I, van Albada ME, Mohnike K, Christesen HT, Emptying S, Salomon-Estebanez M, Greve Rasmussen A, Verrijn Stuart A, van der Linde AAA, Banerjee I, Boot AM. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism. *Horm Res Paediatr* 2018;89(2):82-89.
- 61) Carpenter TO, Whyte MP, Imel EA, Boot AM, Höglér W, Linglart A, Padidela R, van't Hoff W, Mao M, Chen CY, Skrinar A, Kakkis E, San Martin J, Portale AA. Burosumab Therapy for Children with X-linked Hypophosphatemia. *N Engl J Med*. 2018;378(21):1987-1998.
- 62) Kruis RWJ, Schouten-van Meeteren AYN, Finken MJJ, Oostdijk W, van Trotsenburg ASP, Boot AM, Claahsen-van der Grinten HL, van Lindert EJ, Han KS, Hoving EW, Michiels EMC, van Santen HM. Management and consequences of postoperative fluctuations in plasma sodium concentration after pediatric brain tumor surgery in the sellar region: a national cohort analysis. *Pituitary* 2018;21(4):384-392.
- 63) Kalaitzoglou E, Zacharin M, Majaliwa E, de Beaufort C, Chanoine JP, van Wijngaard-de Vugt C, Sperla E, Boot AM, Drop SLS. Development of a Multilingual Global e-learning Curriculum in Pediatric Endocrinology and Diabetes for Front Line Health Care Providers in Resource-limited Countries. *Journal of Medical Internet Research* 2020 Nov 5;4(11):e18555.
- 64) Padidela R, Nilsson O, Makitie O, Beck-Nielsen S, Ariceta G, Schnabel D, Brandi ML, Boot A, Levtschenko E, Smyth M, Jandhyala R, Mughal Z. The international X-linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. *Orphanet J Rare Dis*. 2020 Jun 30;15(1):172.
- 65) Scheffer-Rath ME, Boot AM. The Many Facets of Vitamin D in the Pediatric Population. *Pediatr Endocrinol Rev* 2020 Aug;17(4):293-301
- 66) van Schaik J, van Roessel IMAA, Schouten-van Meeteren NAYN, van Iersel L, Clement SC, Boot AM, Claahsen-van der Grinten HL, Fiocco M, Janssens GO, van Vuurden DG, Michiels EM, Han SKS, van Trotsenburg PASP, Vandertop PWP, Kremer LCM, van Santen HM. High Prevalence of Weight Gain in Childhood Brain Tumor Survivors and Its Association With Hypothalamic-Pituitary Dysfunction. *J Clin Oncol*. 2021 Apr 10;39(11):1264-1273.
- 67) Tacke CE, Terheggen-Lagro SWJ, Boot AM, Plomp AS, Polstra AM, van Rijn RR, Struijs PAA, van den Berg H, Mooij CF. Chondrodysplasia, enchondromas and a chest deformity causing severe pulmonary morbidity in a boy with a PTHLH duplication: A case report. *Bone Rep*. 2021 Apr 15;14:101067.
- 68) Ng SM, de Beaufort C, Boot AM, Becker D, Wolfsdorf JL. Transforming Education through a Global e-Learning Model for Pediatric Diabetes and Endocrinology. *Horm Res Paediatr*. 2021 Jun 30:1-4
- 69) Lebbink CA, Ringers TP, Schouten-van Meeteren AYN, van Iersel L, Clement SC, Boot AM, Claahsen-van der Grinten HL, Janssens GO, van Vuurden DG, Michiels EM, Han KS, van Trotsenburg ASP, Vandertop WP, Kremer LCM, van Santen HM. Prevalence and risk factors of hypothalamic-pituitary dysfunction in infant and toddler childhood brain tumor survivors. *Eur J Endocrinol*. 2021 Sep 6;185(4):597-606.
- 70) Dekker BL, Muller Kobold AC, Brouwers AH, Williams GR, Nies M, Klein Hesselink MS, van der Horst-Schrivers ANA, Havekes B, van den Heuvel-Eibrink MM, van der Pal HJH, Plukker JTM, Ronckers CM, van Santen HM, Burgerhot JGM, Corssmit EPM, Netea-Maier RT, Peeters RP, van Dam EWCM, Boot AM, Tissing WJE, Bocca G, Links TP. Bone Mineral Density in Adult Survivors of Pediatric Differentiated Thyroid Carcinoma: A Longitudinal Follow-Up Study. *Thyroid*. 2021 Nov;31(11):1707-1714.
- 71) Linglart A, Imel EA, Whyte MP, Portale AA, Höglér W, Boot AM, Padidela R, Van't Hoff W, Gottesman GS, Chen A, Skrinar A, Roberts MS, Carpenter TO. Sustained efficacy and safety of burosumab, a monoclonal antibody to FGF23, in children with X-linked hypophosphatemia. *J Clin Endocrinol Metab* 2022 Feb 17;107(3):813-824.
- 72) Ciancia S, van Rijn RR, Höglér W, Appelman-Dijkstra NM, Boot AM, Sas TCJ, Renes JS. Osteoporosis in

children and adolescents: when to suspect and how to diagnose it. *Eur J Pediatr*. 2022; 181(7):2549-2561

73) van Roessel IMAA, van Schaik J, Meeteren AYN, Boot AM, der Grinten HLC, Clement SC, van Iersel L, Han KS, van Trotsenburg ASP, Vandertop WP, Kremer LCM, van Santen HM. Body mass index at diagnosis of a childhood brain tumor; a reflection of hypothalamic-pituitary dysfunction or lifestyle? *Support Care Cancer* 2022;30(7):6093-6102.

74) Abdalla AT, Koedam M, Ls Drop S, Boot AM, Abdullah MA, van der Eerden BCJ. Clinical presentation and molecular genetic analysis of a Sudanese family with a novel mutation in the CYP2R1 gene. *Gene Nov* 30;844:146809.

75) Brandi ML, Ariceta G, Beck-Nielsen SS, Boot AM, Briot K, de Lucas Collantes C, Emma F, Giannini S, Haffner D, Keen R, Levchenko E, Makitie O, Nilsson O, Schnabel D, Tripto-Shkolnik L, Zillikens MC, Liu J, Tudor A, Mughal MZ. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description. *Ther Adv Chronic Dis* 2022 Sep 5;13:20406223221117471.

76) Ng SM, Kalaitzoglou E, Utari A, van Wijngaard-deVugt C, Donaldson M, Wolfsdorf JL, Boot AM, Drop S. 10 years' experience of a global and freely accessible e-Learning website for paediatric endocrinology and diabetes. *Horm Res Paediatr* 2023;96(4):366-375

77) Brinksma A, Suikers E, Kouwenberg D, Lelieveld OTHM, Boot AM, Burgerhof JGM, Tissing WJE. Changes in body size and body composition in survivors of childhood cancer: seven years follow-up of a prospective cohort study. *Clin Nutr*. 2022 Dec;41(12):2778-2785

78) Ciancia S, Höglér W, Sakkars RJB, Appelman-Dijkstra NM, Boot AM, Sas TCJ, Renes JS. Osteoporosis in children and adolescents: how to treat and monitor? *Eur J Pediatr* 2023 Feb; 182(2) :501-511.

79) Draaisma E, Boot AM. Calcium- en fosfaat stofwisseling. *Praktische Pediatrie* Maart 2023, 50-52.

80) Bocca-Tjeertes IF, Boot AM, Brand HK, van Doormaal JJ, Oude Elberink HN. Vertebral fracture in a 7-year-old boy with indolent systemic mastocytosis. *J Allergy Clin Immunol Pract* 2023 Jul 1;S2213-2198(23)00710-9.

81) Scheffer-Rath MEA, Veenstra-Knol HE, Boot AM. A novel mutation in PTHLH in a family with a variable phenotype with brachydactyly, short stature, oligodontia and developmental delay. *Bone Rep* 2023 Jul 15;19:101699.

82) Ariceta G, Beck-Nielsen SS, Boot AM, Brandi ML, Briot K, de Lucas Collantes C, Emma F, Giannini S, Haffner D, Keen R, Levchenko E, Makitie O, Mughal MZ, Nilsson O, Schnabel D, Tripto-Shkolnik L, Liu J, Williams A, Wood S, Zillikens MC. The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data. *Orphanet J Rare Dis* 2023 Sep 27;18(1):304.

83) Vermeulen S, Scheffer-Rath MEA, Besouw MTP, van der Vaart A, de Borst MH, Boot AM. Fibroblast growth factor 23 and calcium-phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes. *J Diabetes* 2024 Jun;16(6):el3500

84) Bosman A, Appelman-Dijkstra NM, Boot AM, de Borst MH, van de Ven AC, de Jongh RT, Bökenkamp A, van den Bergh JP, van der Eerden BCJ, Zillikens MC. Disease Manifestations and Complications in Dutch X-Linked Hypophosphatemia Patients. *Calcif Tissue Int* 2024 Mar;114(3):255-266

85) Saraff V, Boot AM, Linglart A, Semler O, Harvengt P, Williams A, Bailey KMA, Glen F, DavieEH, Wood S, Greentree S, Rylands AJ. A patient-centred and multi-stakeholder co-designed observational prospective study protocol: Example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH). *PLoS One* 2024 Jan 19;19(1):e0295080

86) Boot AM, Ariceta G, Sparre Beck-Nielsen S, Luisa Brandi M, Briot K, de Lucas Collantes C, Giannini S, Haffner D, Keen R, Levchenko E, Mughal MZ, MakitieO, Nilsson O, Schnabel D, Tripto-Shkolnik L, Zillikens MC, Liu J, Tudor A, Emma F. Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis. *Ther Adv Chronic Dis* 2024, Vol. 15:1-15

87) Radidela R, Rayner L, Boot AM. Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during Burosumab treatment. *Bone* 2025; 190

88) Punt LD, Kooijman S, Mutsters NJM, Yue K, van der Kaay DCM, van Tellingen V, Bakker-van Waarde WM, Boot AM, van den Akker ELT, van Boekholt AA, de Groote K, Kruijsen AR, van Nieuwaal-van Maren NHG, Woltering MC, Heijligers M, van der Heyden JC, Bannink EMN, Rinne T, Hannema SE, de Waal WJ, Delemarre LC, Rensen PCN, de Bruin C, van Duyvenvoorde HA, Visser JA, Delhanty PJD, Losekoot M, Wit JM, Joustra SD. Loss-of-Function GHSR Variants Are Associated With Short Stature and Low IGF-I. *J Clin Endocrinol Metab*. 2025 Apr 22;110(5):el303-el314.

89) Aukema, T. W., van Veen, W. J., Boot, A. M., McDermott, A. L. & Hol, M. K. S., "M"Spinning" boneanchored hearing implantation in a 5-year old child: A case report. *Otolaryngology Case Reports* March 2025;34,100656, 2 p., 100656.

Projects

Clinical Trial Experience:

A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the anti-FGF23 Antibody, KRN23, in Pediatric Patients with X-linked Hypophosphatemia (XLH) (2014 -2018).

Growth hormone therapy in prepubertal children with chronic renal failure: evaluation of growth, growth factors, bone mineral density, bone turnover during one year of growth hormone treatment in comparison to paediatric patients with chronic renal failure without growth hormone treatment (1993-1997).

Memberships

Award:

2016 Abstract award Dutch Society Endocrinology

1998 Award of the Scientific Board of the Society for Osteoporosis Research.

Professional Memberships:

1) The European Society of Paediatric Endocrinology (ESPE), since 2000. Chair ESPE e-learning committee 2017 till May 2022, co-chair 2016-2017. Chair of the ESPE Bone Club 2006 - 2009

2) Section Paediatric Endocrinology of the Dutch Paediatric Society. Secretary from 2009 to 2018.

3) Dutch Paediatric Society

4) Dutch Endocrine Society, board member bone network 2019-now

5) Dutch Advisory Board on Growth Hormone

6) Dutch Society of Calcium and Bone Metabolism

7) Expertise group Global Child Health of the Dutch Paediatric Society

8) International Society for Pediatric and Adolescent Diabetes (ISPAD)

9) Global Pediatric Endocrinology and Diabetes (GPED)

10) International Society Children Bone Health since 2024

Other Relevant Information

Other activities:

2024 Tutor of Ragna Wolf, Suriname, for ESPE Clinical Fellowship during 6 months

2022 Nov - present Member of Medical Ethical Committee BEBO (Stichting Beoordeling Ethiek

Biomedisch Onderzoek) and RTPO (Regionale Toetsingscommissie Patiëntgebonden Onderzoek)

2022 Oct 5 Member of Doctoral Committee of Olga Grigic Chavez. Understanding determinants of pediatric developmental health through the prism of dental and skeletal

phenotypes.

2013 June 22-25 Member Program Organising Committee 6th International Conference Children's Bone Health, Rotterdam, the Netherlands.

2013 Sept 4 Co-promotor of Yvette Roke. Antipsychotic-induced hyperprolactinemia in boys with autism spectrum disorders and disruptive behavior disorders.

2012 Dec 13 Co-promotor of Emile Hendriks. Fertility in tall men and women treated with high-dose sex steroids during adolescence and genetic determinants of tall stature.

2009 Oct 24 to Nov 22 Tutor Paediatric Endocrinology Training Centre Nairobi, Kenya.